Trimetazidine demonstrated cardioprotective effects through mitochondrial pathway in a model of acute coronary ischemia

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 386, Issue 3, 2013, Pages 205-215

  Dehina, L ^a   Vaillant, F ^a   Tabib, A ^a   Bui Xuan, B ^a   Chevalier, Ph ^b   Dizerens, N ^a   Bui Xuan, C ^a   Descotes, J ^c   Blanc Guillemaud, V ^d   Lerond, L ^d   Timour, Q ^a,c  

^a UNIVERSITÉ LYON 1   (France)

^b LOUIS PRADEL HOSPITAL   (France)

^c Centre de Pharmacovigilance   (France)

^d INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Cardioprotection; Mitochondria; Trimetazidine; Ventricular fibrillation

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CALCIUM; PHOSPHORYLASE; PLACEBO; REACTIVE OXYGEN METABOLITE; SUCCINATE DEHYDROGENASE; TRIMETAZIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOEQUIVALENCE; CARDIOVASCULAR PARAMETERS; CELL STRUCTURE; CONTROLLED STUDY; DRUG FORMULATION; DRUG RELEASE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HEART ELECTROPHYSIOLOGY; HEART HEMODYNAMICS; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE FIBRILLATION; MITOCHONDRION; NONHUMAN; VENTRICULAR FIBRILLATION THRESHOLD;

ACTION POTENTIALS; ACUTE CORONARY SYNDROME; ANIMALS; CARDIOTONIC AGENTS; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; HEART RATE; MITOCHONDRIA, HEART; REACTIVE OXYGEN SPECIES; SWINE; TRIMETAZIDINE; VENTRICULAR FIBRILLATION;

EID: 84878355773     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-012-0826-z     Document Type: Article

References (45)

1. Argaud L, Gomez L, Gateau-Roesch O, Couture-Lepetit E, Loufouat J, Robert D, Ovize M (2005) Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury. J Mol Cell Cardiol 39:893-899
2. Aupetit JF, Timour Q, Larbre J, Loufoua-Moundanga J, Kioueh I, Lopez M (1993) Arrhythmogenicity of antiarrhythmic drugs and intraventricular conduction disorders: possible aggravation by myocardial ischemia. Study in the porcine in situ heart. Cardiovasc Drugs Ther 7:217-223
3. Aupetit JF, Timour Q, Loufoua-Moundanga J, Barral-Cadiere L, Lopez M, Freys M (1995) Profibrillatory effects of lidocaine in the acutely ischemic porcine heart. J Cardiovasc Pharmacol 25:810-816
4. Aupetit JF, Frassati D, Bui-Xuan B, Freysz M, Faucon G, Timour Q (1998) Efficacy of a beta-adrenergic receptor antagonist, propranolol, in preventing ischaemic ventricular fibrillation: dependence on heart rate and ischaemia duration. Cardiovasc Res 37:646-655
5. Aupetit JF, Bui-Xuan B, Kioueh I, Loufoua J, Frassati D, Timour Q (2000) Opposite change with ischaemia in the antifibrillatory effects of class I and class IV antiarrhythmic drugs resulting from the alteration in ion transmembrane exchanges related to depolarisation. Can J Physiol Pharmacol 78:208-216
6. Boucher FR, Hearse DJ, Opie LH (1994) Effects of trimetazidine on ischemic contracture in isolated perfused rat hearts. J Cardiovasc Pharmacol 24(1):45-49
7. Bui-Xuan B, Aupetit JF, Freysz M, Loufoua J, Faucon G, Timour Q (1996) Cardiac beta-adrenoreceptor activation and ventricular fibrillation under normal and ischemic conditions. Cardiovasc Res 32:1056-1063
8. Bussemaker J, van Beek JH, Groeneveld AB, Hennekes M, Teerlink T, Thijs LG (1994) Local mitochondrial enzyme activity correlates with myocardial blood flow at basal workloads. J Mol Cell Cardiol 26(8):1017-1028
9. Cardiac Arrhythmia Suppression Trial (CAST) Investigator (1991) Mortality and morbidity in patients receiving encainide, flecainide or placebo. N Engl J Med 324:781-788
10. Cardiac Arrhythmia Suppression Trial (CAST) Investigators (1989) Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321:406-412
11. Chalmers G, Roy R, Edgerton V (1992) Variation and limitations in fiber enzymatic and size responses in hypertrophied muscle. J Appl Physiol 73(2):631-641
12. Dalla-Volta S, Maraglino G, Della-Valentina P, Viena P, Desideri A (1990) Comparison of trimetazidine with nifedipine in effort angina. A double-blind, crossover study. Cardiovasc Drugs Ther 4:853-860
13. Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P (1994) Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 37:279-288
14. Dong Z, Saikumar P, Weinberg JM, Venkatachalam MA (2006) Calcium in cell injury and death. Annu Rev Pathol 1:405-434
15. Fujii M, Chambers DJ (2005) Myocardial protection with intermittent cross-clamp fibrillation: does preconditioning play a role? Eur J Cardiothorac Surg 28:821-831
16. Génissel P, Chodjania Y, Demolis JL, Ragueneau I, Jaillon P (2004) Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy volunteers. Eur J Drug Metab Pharmacokinet 29:61-68
17. Grynberg A (2000) Role of membrane lipids in myocardial cytoprotection. Arch Mal Coeur Vaiss 93:175-182
18. Hicks JJ, Montes-Cortes DH, Cruz-Dominguez MP, Medina-Santillan R, Olivares-Corichi IM (2007) Antioxidants decrease reperfusion induced arrhythmias in myocardial infarction with ST-elevation. Front Biosci 12:2029-2037
19. Kantor PF, Lucien A, Kozak R (2000) The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 86:487-489
20. King L, Opie L (1998) Glucose and glycogen utilisation in myocardial ischemia - changes in metabolism and consequences for the myocyte. Mol Cell Biochem 180(1-2):3-26
21. Kristián T, Siesjö BK (1996) Calcium-related damage in ischemia. Life Sci 59:357-367
22. Kudo N, Barr AJ, Barr RL, Desai S, Lopaschuk GD (1995) High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 270:17513-17520
23. Linderholm H, Essen-Gustavsson B, Thornell L (1990) Low succinate dehydrogenase (SDH) activity in a patient with a hereditary myopathy with paroxysmal myoglobinuria. J Intern Med 228(1):43-52
24. Maddika S, Elimban V, Chapman D, Dhalla N (2009) Role of oxidative stress in ischemia-reperfusion-induced alterations in myofibrillar ATPase activities and gene expression in the heart. Can J Physiol Pharmacol 87(2):120-129
25. Marin-Garcia J, Ananthakrishnan R, Goldenthal MJ (1998) Human mitochondrial function during cardiac growth and development. Mol Cell Biochem 179(1-2):21-26
26. Monteiro P, Duarte AI, Goncalves LM, Moreno A, Providencia LA (2000) Protective effect of trimetazidine on myocardial mitochondrial function in an ex vivo model of global myocardial ischemia. Eur J Pharmacol 503:123-128
27. Morin D, Sapena R, Elimadi A, Testa B, Labidalle S, Le Ridant A (2000) [(3)H]-trimetazidine mitochondrial binding sites: regulation by cations, effect of trimetazidine derivatives and other agents and interaction with an endogenous substance. Br J Pharmacol 130(3):655-663
28. Morin D, Assaly R, Paradis S, Berdeaux A (2009) Inhibition of mitochondrial membrane permeability as a putative pharmacological target for cardioprotection. Curr Med Chem 16:4382-4398
29. Moshal KS, Metreveli N, Frank I, Tyagi SC (2008) Mitochondrial MMP activation, dysfunction and arrhythmogenesis in hyperhomocysteinemia. Curr Vasc Pharmacol 6:84-92
30. Noble MI, Belcher PR, Drake-Holland AJ (1995) Limitation of infarct size by trimetazidine in the rabbit. Am J Cardiol 76:41B-44B
31. Onay-Besikci A, Ozkan SA (2008) Trimetazidine revisited: a comprehensive review of the pharmacological effects and analytical techniques for the determination of trimetazidine. Cardiovasc Ther 26:147-165
32. Pauly DF, Pepine CJ (2004) Ischemic heart disease: metabolic approaches to management. Clin Cardiol 27:439-441
33. Phillips D, Aponte AM, French SA, Chess DJ, Balaban RS (2009) Succinyl-CoA synthetase is a phosphate target for the activation of mitochondrial metabolism. Biochemistry 48(30):7140-7149
34. Stanley WC (2004) Myocardial energy metabolism during ischemia and the mechanisms of metabolic therapies. J Cardiovasc Pharmacol Ther 9(suppl 1):S31-S45
35. Szwed H (2004) Clinical benefits of trimetazidine in patients with recurrent angina. Coron Artery Dis Suppl 1:S17-S21
36. Tabib A, Loire R (1981) Quantitative morphometry of myocardial necrosis. Anatomical and enzymatic correlates, clinical index for estimating the amount of necrosed tissue. Arch Mal Coeur Vaiss 74:641-648
37. Tikhaze AK, Lankin VZ, Zharova EA, Kolycheva SV (2000) Trimetazidine as indirect antioxidant. Bull Exp Biol Med 130:951-953
38. Timour Q, Aupetit JF, Loufoua-Moundanga J, Gerentes-Chassagne I, Kioueh I, Faucon G (1991) Class I antiarrhythmic drugs and myocardial ischaemia: study in the pig heart in situ. Naunyn-Schmiedeberg's Arch Pharmacol 343:645-651
39. Timour Q, Aupetit JF, Loufoua-Moundanga JL, Barral-Cadiere L, Freysz M, Faucon G (1994) Demonstration of the fibrillatory effect of class I anti-arrhythmia agents based on the time of fibrillation onset and electrical threshold in myocardial ischemia. Therapie 49(4):349-353
40. Timour Q, Bui-Xuan B, Faucon G, Aupetit JF (1996) Delay by calcium antagonsits, amlodipine, of the onset of primary ventricular fibrillation in myocardial ischemia. Cardiovasc Drugs Ther 10:447-454
41. Vaillant F, Tsibiribi P, Bricca G, Bui-Xuan B, Bescond-Jacquet A, Tabib A, Descotes J, Timour Q (2008a) Trimetazidine protective effect against ischemia-induced susceptibility to ventricular fibrillation in pigs. Cardiovasc Drugs Ther 22:29-36
42. Vaillant F, Timour Q, Descotes J, Manati W, Belhani D, Bui-Xuan B (2008b) Ivabradine induces an increase in ventricular fibrillation threshold during acute myocardial ischemia: an experimental study. J Cardiovasc Pharmacol 52:548-554
43. Veitch K, Maisin L, Hue L (1995) Trimetazidine effects on the damage to mitochondrial functions caused by ischemia and reperfusion. Am J Cardiol 76:25B-30B
44. Wolff AA, Rotmensch HH, Stanley WC (2002) Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective. Heart Fail Rev 7:187-203
45. Zhang J, Li X, Mueller M, Wang Y, Zong C, Deng N (2008) Systematic characterization of the murine mitochondrial proteome using functionally validated cardiac mitochondria. Proteomics 8:1564-1575